Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Open-Label Study for Treatment of Early to Moderate Stage Multiple System Atrophy Patients With the Investigational Allogeneic Cell Therapy Product, hOMSC300

NCT05698017 is registered in ClinicalTrials.gov with Cytora Ltd. as lead sponsor.

NCT NCT05698017
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05698017 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Open-Label Study for Treatment of Early to Moderate Stage Multiple System Atrophy Patients With the Investigational Allogeneic Cell Therapy Product, hOMSC300
Lead sponsor
Cytora Ltd.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
November 7, 2022
Completion date
February 19, 2026
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

msa - multiple system atrophy, multiple system atrophy